covid-19 has since spread rapidly throughout many countries and has been declared to be a pandemic . in an effort to contain and mitigate the spread of covid-19 , many countries , including the united states , canada and countries in europe and asia , have imposed unprecedented restrictions on travel , business operations and public gatherings , and there have been business closures and limitations on business operations , which have resulted in a substantial reduction in economic activity . in march 2020 , in assessing the evolving covid-19 pandemic and related governmental restrictions , the emerging challenges for clinical trial execution within our studies and across the industry , and the need of healthcare facilities and providers to prioritize resources for management of the pandemic , we made the decision to temporarily pause new patient enrollment and new site activation in the proclaim-cx-2009-001 study of praluzatamab ravtansine . this study included a phase 2 expansion designed to evaluate praluzatamab ravtansine in patients with various cancers , including hormone receptor-positive ( “ hr+ ” ) , human epidermal growth factor receptor 2 ( “ her2 ” ) -non-amplified breast cancer . since then , we have revised our strategy for praluzatamab ravtansine to also include patients with triple-negative breast cancer ( “ tnbc ” ) . a new three-arm study , cx-2009-002 , was initiated in the fourth quarter of 2020 targeting investigators who treat breast cancer . arms a and b will evaluate praluzatamab ravtansine monotherapy at 7 mg/kg administered every three weeks in patients with hr+/her2-non-amplified breast cancer and tnbc , respectively . arm c will evaluate praluzatamab ravtansine in combination with pacmilimab in patients with tnbc . approximately 40 evaluable patients will be enrolled into each arm of the study . we also made the strategic decision , in march 2020 , to terminate the proclaim-cx-072-002 study evaluating pacmilimab in combination with ipilimumab in melanoma . this decision followed a re-evaluation of the evolving clinical , competitive and commercial landscapes in immuno-oncology , along with the impact of the covid-19 pandemic , and allowed for resources to be redirected towards our potential first-in-class assets , including a combination of praluzatamab ravtansine and pacmilimab , and to the generation of additional clinical candidates for advancement to the filing of inds and human testing . 81 we continue to work with our partner , abbvie , o n the clinical development of cx-2029 , and , in the fourth quarter of 2020 , we dosed the first patient in the phase 2 expansion study in patients with squamous non-small cell lung cancer , h ead and neck squamous cell cancer , esophageal cancer and diffuse large b-cell lymphoma . in addition , bristol myers squibb initiated a randomized phase 2 study evaluating bms-986249 , a probody version of ipilimumab , as monotherapy or in combination with its anti pd-1 antibody , nivolumab , in patients with metastatic melanoma . this study has been modified to include three additional single-arm cohorts : advanced hepatocellular carcinoma , metastatic castration-resistant prostate cancer , and unresectable locally advanced or metastatic tnbc . bristol myers squibb continues its phase 1 dose-escalation study of bms-986288 , a probody version of non- fucosylated ipilimumab . on february 27 , 2020 , we entered into an open market sale agreement ( the “ sales agreement ” ) with jefferies llc ( “ jefferies ” ) , to sell shares of our common stock , par value $ 0.00001 per share , with aggregate gross sales proceeds of up to $ 75,000,000 , from time to time , through an at the market offering under which jefferies will act as sales agent . during the year ended december 31 , 2020 , we sold 1,535,217 shares of our common stock for aggregate gross proceeds of $ 11.7 million under the sales agreement . pursuant to the sales agreement , jefferies , as sales agent , received a commission of 3.0 % of the gross sales price for shares of common stock sold under the sales agreement . we do not have any product candidates approved for sale , and we continue to incur significant research and development and general administrative expenses related to our operations . we are not profitable and have incurred losses in each year since our founding in 2008. our net loss was $ 32.9 million , $ 102.2 million and $ 84.6 million for 2020 , 2019 and 2018 , respectively . as of december 31 , 2020 and 2019 , we had an accumulated deficit of $ 450.1 million and $ 417.2 million , respectively . we expect to continue to incur significant losses for the foreseeable future . the covid-19 outbreak and any preventative or protective actions that we or our collaboration partners may take in respect of this virus may result in a period of further disruption for our clinical trials , manufacturing , research , financial reporting capabilities and operations generally and could potentially impact our patients , partners , employees and third parties . any resulting financial impact can not be reasonably estimated at this time but may materially affect the business and our financial condition and results of operations . the extent to which the covid-19 pandemic impacts our results will depend on future developments , which are highly uncertain and can not be predicted , including new information which may emerge concerning the severity of covid-19 and the actions necessary to contain the virus or treat its impact , among others . although our operations have been modified , they are continuing at a reduced operational rate . currently , it is not possible to predict how long the pandemic will last or the time that it will take for economic activity to return to its prior levels . story_separator_special_tag interest income and other expense , net replace_table_token_4_th interest income interest income decreased by $ 6.5 million for 2020 compared to 2019. the decrease was primarily attributable to lower average cash , cash equivalents and short-term investments during 2020 and lower interest rates as we experienced a sharp decrease in interest rates starting in march 2020. other expense , net other expense , net decreased by $ 0.1 million for 2020 compared to 2019. the decrease was primarily attributable to a decrease in foreign currency losses resulting from the strengthening of the u.s. dollar against the euro and british pound sterling . provision for ( benefit from ) income taxes year ended december 31 , 2020 2019 change ( in thousands ) provision for ( benefit from ) income taxes $ ( 13,911 ) $ ( 427 ) $ ( 13,484 ) income tax benefit increased by $ 13.5 million for 2020 compared to 2019. the income tax benefit of $ 13.9 million for 2020 was generated due to the recognition of net operating loss carrybacks under the cares act , which generated a tax refund of taxes paid for 2018. the income tax benefit of $ 0.4 million for 2019 was primarily due to a true-up of 2018 federal income tax expense and an unrealized gain on the available-for-sale securities recorded in other comprehensive income for 2019. discussion of 2018 items and the year-to-year comparisons between 2019 and 2018 that are not included in this form 10-k can be found in “ management 's discussion and analysis of financial condition and results of operations ” in part ii , item 7 of our annual report on form 10-k for the year ended december 31 , 2019 filed on february 27 , 2020 . 87 liquidity and capital resources sources of liquidity as of december 31 , 2020 , we had cash , cash equivalents and short-term investments of $ 316.1 million and an accumulated deficit of $ 450.1 million , compared to cash , cash equivalents and short-term investments of $ 296.1 million and an accumulated deficit of $ 417.2 million as of december 31 , 2019. additionally , in january and february 2021 in an underwritten public offering of our common stock , we raised an aggregate net proceeds of approximately $ 107.7 million . to date , we have financed our operations primarily through sales of our common stock in conjunction with the ipo , subsequent stock offerings and through our at-the-market offering , sales of our convertible preferred securities prior to our ipo and payments received under our collaboration agreements . based upon our current operating plan , we expect our existing capital resources will be sufficient to fund operations for a period of at least twelve months from the date the financial statements included in this report are issued . however , if the anticipated operating results and future financing are not achieved in future periods , our planned expenditures may need to be reduced in order to extend the time period over which the then-available resources would be able to fund the operations . the amounts and timing of our actual expenditures depend on numerous factors , including the progress of our preclinical and clinical development efforts , the results of any clinical trials and other studies , our operating costs and expenditures and other factors described under the caption “ risk factors ” in this annual report on form 10-k. the cost and timing of developing our products , including praluzatamab ravtansine ( cx-2009 ) , cx-2029 , and pacmilimab ( cx-072 ) are highly uncertain , are subject to substantial risks and many changes . as such , we may alter our expenditures as a result of contingencies such as the failure of one or all of our product candidates currently in clinical development , the acceleration of one or all of our product candidates in clinical development , the initiating of clinical trials for additional product candidates , the identification of more promising product candidates in our research efforts or unexpected operating costs and expenditures . we will need to raise additional funds in the future . there can be no assurance , however , that such efforts will be successful or that , in the event that they are successful , the terms and conditions of such financing will be favorable to us . summary statement of cash flows the following table summarizes our cash flows for the periods presented : replace_table_token_5_th story_separator_special_tag amounts , timing and likelihood of such payments are not known . see part ii . item 8. financial statements and supplementary data , note 9 - “ research and collaboration agreements ” in the accompanying notes to the financial statements for more information . we enter into agreements in the normal course of business with cros for clinical trials and with vendors for pre-clinical studies and other services and products for operating purposes , which are cancelable at any time by us , generally upon 30 to 60 days prior written notice . these payments are not included in the above table of contractual obligations . the above table also excludes unrecognized tax benefits of $ 6.5 million as of december 31 , 2020 because these uncertain tax positions , if recognized , would be an adjustment to our deferred tax assets , which are subject to a valuation allowance . segment information we have one primary business activity and operate as one reportable segment . critical accounting policies and estimates our management 's discussion and analysis of our financial condition and results of operations is based on our financial statements , which have been prepared in accordance with united states generally accepted accounting principles ( “ u.s . gaap ” ) . the preparation of these financial statements requires our management to make judgments and estimates that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the

cash flows from operating activities 2020 during the year ended december 31 , 2020 , cash provided by operating activities was $ 5.3 million , which consisted of a net loss of $ 32.9 million , adjusted by non-cash charges of $ 20.1 million and a net increase of $ 18.1 million relating to the change of our net operating assets and liabilities . the non-cash charges primarily consisted of $ 14.8 million in stock-based compensation , $ 2.9 million in non-cash lease expense and $ 2.6 million in depreciation and amortization , which amounts were partially offset by $ 0.2 million in accretion of discounts on our short-term investments . the change of our net operating assets and liabilities was primarily due to : a net increase of $ 30.9 million in deferred revenue resulting primarily from the $ 80.0 million upfront payment from astellas as well as the $ 40.0 million milestone payment from abbvie , partially offset by the continued recognition of deferred revenue from other existing customers ; an increase of $ 0.1 million in cash flows from prepaid expenses and other current assets ; a decrease of $ 0.2 million in cash flows from other assets ; a decrease of $ 11.0 million in accrued liabilities primarily due to payment of $ 7.5 million for the immunogen 2019 license and $ 2.8 million for lease liabilities ; 88 a decrease in cashflow of $ 0.8 million from accounts receivable primarily related to research and development service fees due from astellas pursuant to the astellas agreement ; and a decrease in cashflow of $ 0.9 million from accounts payable . 2019 during the year ended december 31 , 2019 , cash used in operating activities was $ 140.5 million , which consisted of a net loss of $ 102.2 million , adjusted by non-cash charges of $ 23.8 million and a net decrease of $ 62.1 million relating to the change in our net operating assets and liabilities .


 Write a concise suspicious activity report of the following text delimited by triple backquotes. Return your response as a formal report which covers the key points highlighting the location,dates,entity names and account holder information in chronological order of the text.
     ```cash flows from operating activities 2020 during the year ended december 31 , 2020 , cash provided by operating activities was $ 5.3 million , which consisted of a net loss of $ 32.9 million , adjusted by non-cash charges of $ 20.1 million and a net increase of $ 18.1 million relating to the change of our net operating assets and liabilities . the non-cash charges primarily consisted of $ 14.8 million in stock-based compensation , $ 2.9 million in non-cash lease expense and $ 2.6 million in depreciation and amortization , which amounts were partially offset by $ 0.2 million in accretion of discounts on our short-term investments . the change of our net operating assets and liabilities was primarily due to : a net increase of $ 30.9 million in deferred revenue resulting primarily from the $ 80.0 million upfront payment from astellas as well as the $ 40.0 million milestone payment from abbvie , partially offset by the continued recognition of deferred revenue from other existing customers ; an increase of $ 0.1 million in cash flows from prepaid expenses and other current assets ; a decrease of $ 0.2 million in cash flows from other assets ; a decrease of $ 11.0 million in accrued liabilities primarily due to payment of $ 7.5 million for the immunogen 2019 license and $ 2.8 million for lease liabilities ; 88 a decrease in cashflow of $ 0.8 million from accounts receivable primarily related to research and development service fees due from astellas pursuant to the astellas agreement ; and a decrease in cashflow of $ 0.9 million from accounts payable . 2019 during the year ended december 31 , 2019 , cash used in operating activities was $ 140.5 million , which consisted of a net loss of $ 102.2 million , adjusted by non-cash charges of $ 23.8 million and a net decrease of $ 62.1 million relating to the change in our net operating assets and liabilities .
```    
 Suspicious Activity Report : covid-19 has since spread rapidly throughout many countries and has been declared to be a pandemic . in an effort to contain and mitigate the spread of covid-19 , many countries , including the united states , canada and countries in europe and asia , have imposed unprecedented restrictions on travel , business operations and public gatherings , and there have been business closures and limitations on business operations , which have resulted in a substantial reduction in economic activity . in march 2020 , in assessing the evolving covid-19 pandemic and related governmental restrictions , the emerging challenges for clinical trial execution within our studies and across the industry , and the need of healthcare facilities and providers to prioritize resources for management of the pandemic , we made the decision to temporarily pause new patient enrollment and new site activation in the proclaim-cx-2009-001 study of praluzatamab ravtansine . this study included a phase 2 expansion designed to evaluate praluzatamab ravtansine in patients with various cancers , including hormone receptor-positive ( “ hr+ ” ) , human epidermal growth factor receptor 2 ( “ her2 ” ) -non-amplified breast cancer . since then , we have revised our strategy for praluzatamab ravtansine to also include patients with triple-negative breast cancer ( “ tnbc ” ) . a new three-arm study , cx-2009-002 , was initiated in the fourth quarter of 2020 targeting investigators who treat breast cancer . arms a and b will evaluate praluzatamab ravtansine monotherapy at 7 mg/kg administered every three weeks in patients with hr+/her2-non-amplified breast cancer and tnbc , respectively . arm c will evaluate praluzatamab ravtansine in combination with pacmilimab in patients with tnbc . approximately 40 evaluable patients will be enrolled into each arm of the study . we also made the strategic decision , in march 2020 , to terminate the proclaim-cx-072-002 study evaluating pacmilimab in combination with ipilimumab in melanoma . this decision followed a re-evaluation of the evolving clinical , competitive and commercial landscapes in immuno-oncology , along with the impact of the covid-19 pandemic , and allowed for resources to be redirected towards our potential first-in-class assets , including a combination of praluzatamab ravtansine and pacmilimab , and to the generation of additional clinical candidates for advancement to the filing of inds and human testing . 81 we continue to work with our partner , abbvie , o n the clinical development of cx-2029 , and , in the fourth quarter of 2020 , we dosed the first patient in the phase 2 expansion study in patients with squamous non-small cell lung cancer , h ead and neck squamous cell cancer , esophageal cancer and diffuse large b-cell lymphoma . in addition , bristol myers squibb initiated a randomized phase 2 study evaluating bms-986249 , a probody version of ipilimumab , as monotherapy or in combination with its anti pd-1 antibody , nivolumab , in patients with metastatic melanoma . this study has been modified to include three additional single-arm cohorts : advanced hepatocellular carcinoma , metastatic castration-resistant prostate cancer , and unresectable locally advanced or metastatic tnbc . bristol myers squibb continues its phase 1 dose-escalation study of bms-986288 , a probody version of non- fucosylated ipilimumab . on february 27 , 2020 , we entered into an open market sale agreement ( the “ sales agreement ” ) with jefferies llc ( “ jefferies ” ) , to sell shares of our common stock , par value $ 0.00001 per share , with aggregate gross sales proceeds of up to $ 75,000,000 , from time to time , through an at the market offering under which jefferies will act as sales agent . during the year ended december 31 , 2020 , we sold 1,535,217 shares of our common stock for aggregate gross proceeds of $ 11.7 million under the sales agreement . pursuant to the sales agreement , jefferies , as sales agent , received a commission of 3.0 % of the gross sales price for shares of common stock sold under the sales agreement . we do not have any product candidates approved for sale , and we continue to incur significant research and development and general administrative expenses related to our operations . we are not profitable and have incurred losses in each year since our founding in 2008. our net loss was $ 32.9 million , $ 102.2 million and $ 84.6 million for 2020 , 2019 and 2018 , respectively . as of december 31 , 2020 and 2019 , we had an accumulated deficit of $ 450.1 million and $ 417.2 million , respectively . we expect to continue to incur significant losses for the foreseeable future . the covid-19 outbreak and any preventative or protective actions that we or our collaboration partners may take in respect of this virus may result in a period of further disruption for our clinical trials , manufacturing , research , financial reporting capabilities and operations generally and could potentially impact our patients , partners , employees and third parties . any resulting financial impact can not be reasonably estimated at this time but may materially affect the business and our financial condition and results of operations . the extent to which the covid-19 pandemic impacts our results will depend on future developments , which are highly uncertain and can not be predicted , including new information which may emerge concerning the severity of covid-19 and the actions necessary to contain the virus or treat its impact , among others . although our operations have been modified , they are continuing at a reduced operational rate . currently , it is not possible to predict how long the pandemic will last or the time that it will take for economic activity to return to its prior levels . story_separator_special_tag interest income and other expense , net replace_table_token_4_th interest income interest income decreased by $ 6.5 million for 2020 compared to 2019. the decrease was primarily attributable to lower average cash , cash equivalents and short-term investments during 2020 and lower interest rates as we experienced a sharp decrease in interest rates starting in march 2020. other expense , net other expense , net decreased by $ 0.1 million for 2020 compared to 2019. the decrease was primarily attributable to a decrease in foreign currency losses resulting from the strengthening of the u.s. dollar against the euro and british pound sterling . provision for ( benefit from ) income taxes year ended december 31 , 2020 2019 change ( in thousands ) provision for ( benefit from ) income taxes $ ( 13,911 ) $ ( 427 ) $ ( 13,484 ) income tax benefit increased by $ 13.5 million for 2020 compared to 2019. the income tax benefit of $ 13.9 million for 2020 was generated due to the recognition of net operating loss carrybacks under the cares act , which generated a tax refund of taxes paid for 2018. the income tax benefit of $ 0.4 million for 2019 was primarily due to a true-up of 2018 federal income tax expense and an unrealized gain on the available-for-sale securities recorded in other comprehensive income for 2019. discussion of 2018 items and the year-to-year comparisons between 2019 and 2018 that are not included in this form 10-k can be found in “ management 's discussion and analysis of financial condition and results of operations ” in part ii , item 7 of our annual report on form 10-k for the year ended december 31 , 2019 filed on february 27 , 2020 . 87 liquidity and capital resources sources of liquidity as of december 31 , 2020 , we had cash , cash equivalents and short-term investments of $ 316.1 million and an accumulated deficit of $ 450.1 million , compared to cash , cash equivalents and short-term investments of $ 296.1 million and an accumulated deficit of $ 417.2 million as of december 31 , 2019. additionally , in january and february 2021 in an underwritten public offering of our common stock , we raised an aggregate net proceeds of approximately $ 107.7 million . to date , we have financed our operations primarily through sales of our common stock in conjunction with the ipo , subsequent stock offerings and through our at-the-market offering , sales of our convertible preferred securities prior to our ipo and payments received under our collaboration agreements . based upon our current operating plan , we expect our existing capital resources will be sufficient to fund operations for a period of at least twelve months from the date the financial statements included in this report are issued . however , if the anticipated operating results and future financing are not achieved in future periods , our planned expenditures may need to be reduced in order to extend the time period over which the then-available resources would be able to fund the operations . the amounts and timing of our actual expenditures depend on numerous factors , including the progress of our preclinical and clinical development efforts , the results of any clinical trials and other studies , our operating costs and expenditures and other factors described under the caption “ risk factors ” in this annual report on form 10-k. the cost and timing of developing our products , including praluzatamab ravtansine ( cx-2009 ) , cx-2029 , and pacmilimab ( cx-072 ) are highly uncertain , are subject to substantial risks and many changes . as such , we may alter our expenditures as a result of contingencies such as the failure of one or all of our product candidates currently in clinical development , the acceleration of one or all of our product candidates in clinical development , the initiating of clinical trials for additional product candidates , the identification of more promising product candidates in our research efforts or unexpected operating costs and expenditures . we will need to raise additional funds in the future . there can be no assurance , however , that such efforts will be successful or that , in the event that they are successful , the terms and conditions of such financing will be favorable to us . summary statement of cash flows the following table summarizes our cash flows for the periods presented : replace_table_token_5_th story_separator_special_tag amounts , timing and likelihood of such payments are not known . see part ii . item 8. financial statements and supplementary data , note 9 - “ research and collaboration agreements ” in the accompanying notes to the financial statements for more information . we enter into agreements in the normal course of business with cros for clinical trials and with vendors for pre-clinical studies and other services and products for operating purposes , which are cancelable at any time by us , generally upon 30 to 60 days prior written notice . these payments are not included in the above table of contractual obligations . the above table also excludes unrecognized tax benefits of $ 6.5 million as of december 31 , 2020 because these uncertain tax positions , if recognized , would be an adjustment to our deferred tax assets , which are subject to a valuation allowance . segment information we have one primary business activity and operate as one reportable segment . critical accounting policies and estimates our management 's discussion and analysis of our financial condition and results of operations is based on our financial statements , which have been prepared in accordance with united states generally accepted accounting principles ( “ u.s . gaap ” ) . the preparation of these financial statements requires our management to make judgments and estimates that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the

